Skip to main content

Explaining Treatment Regimens to Patients with HR+/HER2- Metastatic Breast Cancer

Breast Cancer, Video
Videos
Dr Thomas Bachelot is careful to set reasonable expectations for his patients with HR+/HER2- metastatic breast cancer regarding how long their treatment will last and how it will impact them.

Related Items

Adding Ribociclib to Endocrine Therapy May Reduce Risk for Recurrence in HR-Positive, HER2-Negative, Early Breast Cancer
By Patricia Stewart
July 2023 Vol 16, No 4 – Online Only
ASCO 2023 Highlights, Breast Cancer
FDA Updates Mammography Regulations in MQSA Final Rule
May 2023 Vol 16, No 3
Breast Cancer, Healthcare Policy
Pausing Endocrine Therapy to Become Pregnant Appears Safe for Women with Breast Cancer
By Patricia Stewart
March 2023 Vol 16, No 2
Breast Cancer, SABCS Highlights
Factors Associated with Greater Risk for Abemaciclib Discontinuation in Patients with Early-Stage Breast Cancer
By William King
TOP - November 2022 Vol 15, No 6
Breast Cancer